LIPA and metabolic dysfunction-associated steatotic liver disease: Continued study will be necessary to verify the utility of LAL as a biomarker of NAFLD, and it remains to be seen whether LAL activity could be used to identify patients earlier in the NAFLD progression than existing methods.